M&A / Deals Gilead Sciences completes Tubulis acquisition for $5bn Pharmaceutical TechnologyGilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn.Read full story pharminent May 22, 2026 (Last updated: May 22, 2026) Pharmaceutical Technology Gilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: In Alzheimer’s, Bristol Myers sees big promise beyond amyloidNext: GBL joins CVC in 10.7bn takeover bid for Recordati Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
